Atlas Trials

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Clinical trial NCT04602533 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04602533
Sponsor
Michael Hopp
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer Limited Stage
Start date
2020-12-21
Primary completion
2026-12-31
Enrollment
105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.